No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ATNM Actinium
- 7.110
- -0.110-1.52%
Close Jul 19 16:00 ET
- 7.400
- +0.290+4.08%
Post 19:54 ET
211.76MMarket Cap-4157P/E (TTM)
7.250High7.050Low92.73KVolume7.240Open7.220Pre Close661.02KTurnover0.32%Turnover RatioLossP/E (Static)29.78MShares10.24052wk High4.83P/B206.17MFloat Cap4.00052wk Low--Dividend TTM29.00MShs Float450.000Historical High--Div YieldTTM2.77%Amplitude3.000Historical Low7.128Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Nusano and PharmaLogic Announce Strategic Supply Agreement to Enable Current and Emerging Radiopharmaceuticals
VALENCIA, Calif. and BOCA RATON, Fla., July 10, 2024 /PRNewswire/ -- Nusano Inc. ("Nusano"), a physics company transforming the production of medical radioisotopes, and PharmaLogic Holdings Corp. ("
Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients With Extensive-stage Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr platform to design and develop tunable, precision
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
H.C. Wainwright Maintains Actinium(ATNM.US) With Buy Rating, Maintains Target Price $50
H.C. Wainwright analyst Joseph Pantginis maintains $Actinium(ATNM.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 37.3% and
Express News | HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target
Actinium Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 515.76% HC Wainwright & Co. $50 → $50 Reiterates Buy → Buy 05/21/2024 515.76% HC Wainwright & C
Comments
$Actinium(ATNM.US$ Reuters· 2 mins ago
Actinium Pharmaceuticals Inc- Iomab-B Achieved Primary Endpoint of Durable Complete Remission (Dcr) With High Statistical Significance (P<0.0001)
Actinium Pharmaceuticals Inc- Iomab-B Achieved Primary Endpoint of Durable Complete Remission (Dcr) With High Statistical Significance (P<0.0001)
1
$Actinium(ATNM.US$ Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did no...
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did no...
1
$Actinium(ATNM.US$
NEWS
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals announced that the Phase 3 SIERRA trial results of Iomab-B will be presented at the EHA 2024 Congress. The trial demonstrated significant survival benefits in older patients wit...
NEWS
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals announced that the Phase 3 SIERRA trial results of Iomab-B will be presented at the EHA 2024 Congress. The trial demonstrated significant survival benefits in older patients wit...
3
2
$Actinium(ATNM.US$
NEWS
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
NEWS
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg